Modern Vaccines Adjuvants Formulation

2-4 May 2018, LUMC – Leiden University Medical Center, Leiden, The Netherlands

  • Increase font size
  • Default font size
  • Decrease font size

Day Two

Final Conference Programme | Thursday 3rd May 2018

SESSION 5:
PLENARY SESSION IV

Moderator: Maria Lazaro (SEPPIC, Paris, France)

09.00-09.30
‘TB Vaccines overview’

Tom H.M. Ottenhoff (Leiden University Medical Center, Leiden, The Netherlands)

09.30-10.00
‘Chitosan-based adjuvants: Biopolymer characteristics determine immunogenicity for inactivated influenza vaccines’

Yuri Vasiliev (State Research Institute of Ultrapure Biologicals, St. Petersburg, Russian Federation)

10.00-10.30
‘NHP models for vaccines, adjuvants and delivery systems’

Edmond J. Remarque (Biomedical Primate Research Centre, Rijswijk, The Netherlands)

10.30-11.00
Coffee Break

SESSION 6:
ADJUVANTS I

Moderator: Edmond J. Remarque (Biomedical Primate Research Centre, Rijswijk, The Netherlands)

11.00-11.30
‘The functional effects of the Amplivant adjuvant (TLR1/2 ligand)’

Kees Melief (ISA-Pharmaceuticals BV, Leiden, The Netherlands)

11.30-12.00
‘Advanced kinetic analysis as a tool for formulation development and prediction of vaccine stability’

Sandrine Cigarini (Sanofi Pasteur, Marcy l’Etoile, France)

12.00-12.30
‘Evaluation of TLR-4-agonist and cAMP-based (dmLT) adjuvants in combination for delivery of anti-enterotoxigenic E. coli vaccine candidates by the intradermal or intramuscular routes’

Milton Maciel Jr.1,2, Zoltan Beck2,3, Stefanie Trop1,2, Garry R. Matyas3, Steven Poole1,2, Aaron Kim1,2, Beth Ward1,2, Zuzana Villar1,2, Carl R. Alving3
and Michael G. Prouty1 (1 Naval Medical Research Center, Silver Spring, Maryland, USA; 2 Henry M. Jackson Foundation, Bethesda, Maryland, USA; 3 Walter Reed Army Institute of Research, Silver Spring, Maryland, USA)

12.30-14.00
Lunch Break

SESSION 7:
ADJUVANTS II

Moderator: Jean Haensler (Sanofi Pasteur, Marcy l’Etoile, France)

14.00-14.30
‘Adjuvanted Staphylococcus aureus vaccine an alternative for antibiotic treatment’
Bror Morein (Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden)

14.30-15.00
‘Adjuvant properties of the TLR7/8 agonist 3M-052’

Mark Tomai (3M Company, St Paul, Minnesota, USA)

15.00-15.30
‘Adjuvant safety: Role of T cell derived GPIbα protein in production of pro-inflammatory molecules PGE2 and IL-1β in primary human monocytes activated with muramyl dipeptide adjuvant’

Marina Zaitseva, Fengjie Liu, Tatiana Romantseva, Wells Wu, Rong-Fong Shen and Hana Golding (Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA)

15.30-16.00
Tea Break

SESSION 8:
GENERAL SESSION

Moderator: Mark Tomai (3M Company, St. Paul, Minnesota, USA)

16.00-16.30
‘Adjuvantome: Transcriptome data base for preclinical evaluation of vaccine adjuvant and immunotherapy’

Natsuko Kishishita and Ken J. Ishii (Osaka University, Osaka, Japan)

16.30-17.00
‘Clinical developments with Montanide ISA 51 VG adjuvant: A case study of a lung cancer vaccine (CIMAvax-EGF)’
Maria Lazaro (SEPPIC, Paris, France)

17.00-17.30
‘Characterization of protein vaccines containing an emulsion based adjuvant’
Michelle Archer (IDRI, Seattle, Washington, USA)

 

MVAF 2018 Delegates

Login details will be supplied after you have registered for the event.


MVAF 2018 Sponsors

  • VaxArt
  • Intravacc
  • Bioaster
  • DNAvaccine.com
  • CureVac
  • Aldevron
  • Brenntag
  • EVI
  • IDRI
  • Sanofi Pasteur
  • Seppic
  • hVIVO
  • Inovio Pharmaceuticals
  • NatureGeneTherapy.com

MVAF 2018 Downloads

MVAF 2018 Leaflet

MVAF 2018 Mailing List

Name
E-mail Address
What is 3+2-1?